Table 1.
Baseline patient characteristics of the study cohort.
| Characteristic | Patients (N = 35) |
|---|---|
| Sex, no. (%) | |
| Male | 24 (69) |
| Female | 11 (31) |
| Age, y | |
| Median | 73 |
| Range | 55–88 |
| WHO subtype, no. (%) | |
| RCMD | 9 (26) |
| RAEB-1 | 6 (17) |
| RAEB-2 | 11 (31) |
| CMML | 5 (16) |
| AML | 4 (13) |
| Cytopenias | |
| Grade 2 or 3, no. (%) | 27 (77) |
| ANC, mean (range), x109/L | 0.94 (0.06–7.65) |
| Hemoglobin, mean (range), g/dL | 9.3 (7.3–13.1) |
| Platelets, mean, (range), x109/L | 46 (9–270) |
| IPSS cytogenetic score, no. (%) | |
| Good | 13 (39) |
| Intermediate | 9 (27) |
| Poor | 11 (33) |
| IPSS Category, no. (%) | |
| Low/INT-1 | 15 (43) |
| INT-2/High | 19 (54) |
| Unknown | 1 (3) |
| MD Anderson Risk Category, no. (%) | |
| Low/INT-1 | 7 (20) |
| INT-2/High | 27 (77) |
| Unknown | 1 (3) |
| Baseline bone marrow blast percentage, % | |
| Median | 5 |
| Range | 0.2–23 |
| Prior HMA therapy | |
| Azacitidine, no. (%) | 34 (97) |
| Median no. of cycles/patient | 9 |
| Decitabine, no. (%) | 6 (17) |
| Median no. of cycles/patient | 4 |
Abbreviations: AML, acute myeloid leukemia; ANC, absolute neutrophil count; CMML, chronic myelomonocytic leukemia; HMA, hypomethylating agent; INT, intermediate; IPSS, international prognostic scoring system; RAEB, refractory anemia with excess blasts; RCMD, refractory cytopenia with multilineage dysplasia; WHO, World Health Organization.